This report describes preliminary experiences with the use of gemfibrozil (CI-719) in the treatment of primary endogenous hypertriglyceridxemia. Some studies were also carried out to elucidate the mechanism of action of this new hypolipidxmic agent. The compound appears to be highly effective in lowering serum triglyceride and VLDL levels, but the underlying mechanisms of this action are far from clear.
Twenty patients with serum triglyceride levels above 2.0 mmol/l who were willing to participate in the trial were recruited from the files of hyperlipidemic patients in our Lipid Clinic. There were 2 females and 18 males from 31 to 56 years of age (median 48 years). Twelve patients were overweight (I 16 % to 151 % of ideal body weight), 5 had survived an acute myocardial infarction, and 2 had classical angina pectoris. Ten patients had previously been instructed to consume a lipid lowering diet, which, however, had not significantly influenced their hyperlipidemia. Six patients had used some hypolipidemic drug, but the treatment had been discontinued for at least one month before the start of the present study. Seven patients regularly used various drugs which are not known to affect lipid levels.
On the basis of ultracentrifugal lipoprotein analysis, 9 patients had type IV (VLDL-TG> 1.2 mmol/l, LDL-cholesterol < 5.5 mmol/l), 9 had type Ilb (LDL-cholesterol>5.5 mmol/l), 1 had type III (cholesterol/triglyceride molar ratio in VLDL> 1.0), and I had type V (chylomicrons present in fasting serum) hyperlipoproteinemia.
Lipoprotein analysis of close relatives indicated a definite familial background for the hyperlipoproteinemia in 11 patients.
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At the start of the trial, each patient was informed of the purpose and design of the study and their consent was obtained. The trial was initiated by a six-week pretreatment period, during which the patients received no hypolipidxmic drugs and they were instructed to keep their diet and body weight as constant as possible. Thereafter, gemfibrozil was started at a dose of 800 mg/day (two 200 mg capsules twice daily).
Serum cholesterol (Huang et al. 1961) and triglycerides (Kessler & Lederer 1966) were analysed at two-weekly intervals during the pretreatment period, and at every fourth week during the drug period. Plasma lipoprotein analysis with ultracentrifugal separation of VLDL, LDL and HDL (Havel et al. 1955 ) was carried out twice during the baseline period and after four and 12 treatment weeks. Heparin tests with a specific immunochemical assay of lipoprotein lipase and hepatic lipase activities of postheparin plasma (Huttunen et al. 1975) were performed at six and 10 weeks before treatment and after four weeks of treatment. Oral glucose tolerance tests (I g/kg) with blood-glucose and plasma-insulin assays at 0.1 and 2 h were performed before treatment and after 10 weeks of treatment. All blood samples were taken after the patients had fasted for 12 h. The last dose of gemfibrozil was also taken 12 h before the sampling.
The patients appeared to be highly cooperative, and the adherence has been 100% so far. The only drop-out occurred because of an allergic reaction (see below). Subjective side effects were screened by a questionnaire containing 28 symptoms.
Results
Serum lipids and lipoproteins: The mean values of serum cholesterol and triglycerides before and during gemfibrozil treatment are shown in Fig 1. During the pretreatment period the serum triglyceride level decreased initially by an average of 14%, but stabilization occurred during the four weeks immediately preceding the start of the triglyceride values of20 patients on entering the study (-6 weeks), at the start ofthe drugperiod and afterfour and 12 weeks on gemfibrozil 800 mg/day. One patient with good response discontinued betweenfour and 12 weeks drug period. During the first four-week period of treatment the triglyceride level fell by an average of 460%, and this primary response was well maintained throughout the observation period.
The mean decrease of serum triglycerides during 20 weeks was 44.6-+3.6% (P<0.001).
Only 2 patients appeared to be completely resistant to the drug (I type V and I type IV).
In the remaining subjects the mean decrease in the serum triglyceride level varied from 27% to 720%. In 9 patients the triglyceride level was brought into the normal range, and 12 had values less than 2.0 mmol/l (Fig 2) . There was no correlation between the absolute or relative decrease of serum triglyceride during gemfibrozil treatment and the initial triglyceride level, nor was there any significant difference between the triglyceride responses of type lIb and IV patients. Serum total cholesterol levels were reduced by an average of 10.5 % (P<0.05). The best response was obtained in the type III patient (-40.00%), while no change or a rise of serum cholesterol occurred in 6 patients. Of these, 5 were type IV and 1 type V. The average response of serum cholesterol to gemfibrozil treatment was significantly less in patients with type IV (-5.4%) than in those with type lIb (-12.4%). No correlation was found between the initial serum cholesterol level and the magnitude of the response to gemfibrozil treatment. The distribution of the individual cholesterol values before and during treatment is shown in Fig 3. The normal range of serum cholesterol was reached in only 3 cases.
The mean values of serum lipoproteins and their responses to gemfibrozil are illustrated in Fig 4. The VLDL-triglyceride and VLDLcholesterol were decreased in all but 2 patients (I type IV and 1 type V). The mean reduction of VLDL-triglyceride was -38.2% at four weeks and -44.6% at 12 weeks. In 9 patients the VLDL-triglyceride concentration was maintained within the normal range (less than 1.2 mmol/l) during the treatment. The average decrease of VLDL-cholesterol was -57.8% and -57.5% at four and 12 weeks respectively (P<0.001). The average cholesterol/triglyceride ratio of VLDL was 0.75 before treatment and 0.60 after 12 weeks on the drug. In the type III patient the VLDL cholesterol/ triglyceride ratio was reduced from 1.50 to 1.07.
The mean LDL-triglycoride decreased from 0.66 mmol/l to 0.52 mmol/l (21 %, P<0.01). Patients with type IV hyperlipoproteinemia did not show any significant change in the LDLtriglyceride, however. The LDL-cholesterol behaved differently in type Ilb and type IV patients. Most of the Ilb individuals showed a slight decrease, but the mean change was not significant. On the contrary, the LDL-cholesterol rose during the treatment in 8 of 9 patients with type IV, and the mean level during the drug period was significantly higher than the pretreatment level (P<0.05). The change of LDL-cholesterol showed a highly significant inverse correlation with the pretreatment LDL-cholesterol level ( Fig 5) , whereas no correlation was present between the magnitude of increase of LDLcholesterol and the decrease of VLDL-triglyceride (expressed in either absolute or relative units). The cholesterol/triglyceride ratio of LDL increased from 8.3 to 12.0 during the treatment.
The mean HDL-cholesterol concentration increased by 16% during drug administration. This change was not significant, however (P> 0.05), since a slight increase of HDL-cholesterol occurred already during the pretreatment period. HDL-cholesterol was significantly increased at 12 weeks in comparison with the level at entry (P<0.05). The HDL-triglyceride did not change during treatment.
Postheparin plasma lipase activities: The lipoprotein lipase (LPL) activity of postheparin plasma remained constant during the baseline (no treatment) period. Gemfibrozil increased the activity in all but 1 of the 20 patients ( Fig 6) . In most cases the increase was of slight or moderate degree, the mean change being only + 18.1 % (P<0.001). The decrease of serum triglyceride level (absolute or relative) did not show any significant correlation with the magnitude of increase of LPL activity (Fig 7) . The fall of VLDL-triglyceride and the change of LPL activity during four weeks of gemfibrozil treatment did not correlate with each other either.
The postheparin plasma hepatic lipase (HL) activities before and during gemfibrozil treatment are shown in Fig 8. This activity also increased significantly during administration of the drug, but the change was less consistent than that of LPL. The mean change of HL during four weeks of treatment was +20.6% (P<0.01). There was no correlation between the change of HL and the magnitude of response of serum cholesterol, triglyceride, VLDL or LDL concentrations. both before and during use of the drug. None of them showed a low insulin response at either testing. There was no correlation between the initial serum triglyceride level and the magnitude of plasma insulin response to oral glucose. The increase of postheparin plasma LPL activity during gemfibrozil treatment did not show any correlation with the baseline or treatment period plasma insulin responses (1or 2-h increment).
Side effects: One patient developed an acute generalized allergic skin reaction in the ninth week of treatment. The blood eosinophil count was elevated (7%). After withdrawal of gemfibrozil and administration of oral prednisone, the rash disappeared slowly during two weeks. Questioning about the patient's previous history revealed that he had suffered allergic eczema 15 years earlier and had slight symptoms of bronchial asthma during the last three years. An intracutaneous test with gemfibrozil gave a negative result. The patient did not give his consent for an oral challenge with the drug.
The other patients did not have any subjective symptoms which could have been attributed to gemfibrozil. None complained of significant gastrointestinal, neurological or cutaneous side effects. Nor were muscular weakness, pain, cramps or cardiac arrhythmias recorded. Serum transaminase levels were not elevated during treatment in comparison with the baseline period. Increased levels of serum creatine phosphokinase were found in some patients during treatment. One patient showing a decrease ofthe LPL activity during use ofthe drug, and 1 patient with no decrease ofserum triglyceride (in spite ofan increase ofLPL of106%) are excluded Glucose tolerance and insulin response: The mean values of blood glucose and plasma insulin during a two-hour oral glucose tolerance test are shown in Fig 9. The drug had no influence on fasting blood glucose or on glucose tolerance. Eight patients had impaired glucose tolerance before the treatment and of these only 1 became normal during a 10-week treatment period with gemfibrozil. All patients had normal pretreatment fasting blood glucose (< 5.0 mmol/l). During gemfibrozil treatment, 1 subject had a slightly elevated fasting blood glucose value. The basal plasma insulin level was not significantly changed by the drug. On the other hand, there was a significant increase of the mean onehour plasma insulin value during gemfibrozil treatment (+18.4 %, P<0.05). Five patients were insulin hyper-responders (1 h value >100 ftU/ml) 
Discussion
Gemfibrozil is chemically related to clofibrate and it seems to share many of the properties of that drug. In the present series, of 20 patients with hypertriglyceridxcmia, a prompt and sustained fall of serum total and VLDL-triglyceride and of VLDL-cholesterol was produced by gemfibrozil in a daily dose of 800 mg. Only 2 patients were resistant to the hypolipidcmic action of the drug, and 1 patient with good response had to discontinue the treatment because of a serious allergic reaction, which was probably caused by gemfibrozil.
No secondary failures occurred during 20 weeks of treatment, even though some patients showed fluctuations of the serum triglyceride level.
The resistant patients had type IV and V hyperlipoproteinemia without any apparent exceptional features which could account for their lack of response to the treatment. The type IV patient had two pre-beta bands in agarose gel electrophoresis of isolated VLDL, but a similar pattern was also seen in many of those patients who had a good response to gemfibrozil. The postheparin plasma LPL activity of this patient rose more than the average during treatment and could thus not account for the resistance. No evidence could be obtained for excessive drinking or for failure to take the drug. The type V nonresponder had continuously high but variable serum triglyceride levels (from 7 to 48 mmol/l). He admitted the regular use of alcohol, but was always sober at examination (blood alcohol negative). His postheparin plasma LPL was moderately low (50% of normal average), as is typical for untreated type V patients. During gemfibrozil treatment the LPL activity rose to the normal range, but this increase was not associated with any significant change of serum chylomicron and VLDL triglyceride levels. The possibility remains that ethanol can effectively abolish the lipid lowering effect of gemfibrozil, i.e. the drug is not able to prevent the ethanolinduced stimulation of hepatic VLDL secretion.
The magnitude of the serum total or VLDLtriglyceride response to gemfibrozil was not related to the pretreatment level of either parameter nor to the initial LDL level. Thus, the effectiveness of treatment could not be predicted on the basis of primary lipoprotein phenotype (Ilb or IV). On the other hand, the change of LDL-cholesterol concentration during gemfibrozil treatment was closely dependent on the baseline LDL-cholesterol level: values less than 5.8 mmol/l increased while those above this limit decreased (Fig 5) . In other words, patients with an initially normal LDL level (type IV) showed a reciprocal change of VLDL and LDL, while those having elevated LDL (type Ilb) had either no change or a decrease of this lipoprotein.
The change of LDL-cholesterol was not related to the magnitude of the VLDL-triglyceride or VLDL-cholesterol response. Similar behaviour of LDL has been previously reported by Strisower et al. (1968) in the treatment of different hyperlipoproteinemias with clofibrate. Wilson & Lees (1972) , on the other hand, noted a reciprocal relationship between the changes of LDL and VLDL-cholesterol levels when the latter was modified by diet or clofibrate. Such a relationship was not evident in the present study nor in that of Strisower et al. (1968) . The discrepancy between the results may be due to absence of patients with clearly elevated LDL levels (type Ilb) in the material studied by Wilson & Lees (1972) .
The reasons for the elevation of LDL during treatment are not completely clear. Since the major part of LDL is derived from catabolism of VLDL (Sigurdsson et al. 1975) it seems natural that a drug which increases the lipoprotein lipase activity and presumably also the catabolic rate of VLDL will cause an accumulation of LDL, if the elimination of LDL is not increased simultaneously. However, our data do not provide any good basis for this explanation, since the change of LDL level was not related to the increase of lipoprotein lipase in postheparin plasma, nor to the magnitude of VLDL reduction by gemfibrozil. Another possibility to explain the variable LDL response is to assume that in type Ilb hyperlipoproteinemia the drug suppresses the increased hepatic production of VLDL, while in type IV the hypolipidxmic effect is based more on acceleration of VLDL removal.
The mechanisms by which gemfibrozil lowers the VLDL (and occasionally also the LDL) level remain largely obscure. It is likely that the drug influences both the production and removal of VLDL as seems to be the case in the action of clofibrate (Bierman et al. 1970 , Nikkilii & Kekki 1972 . The effect of gemfibrozil on postheparin plasma LPL activity was much smaller than that of clofibrate (Nikkila et al. 1976) and it is therefore possible that the former drug is a more powerful inhibitor of hepatic VLDL secretion than clofibrate. Even though small increases in the activity of the removal enzyme may account for relatively large decreases in the concentration of a circulating metabolite, the increase of postheparin plasma LPL observed in the present study seems to be too slight to be entirely responsible for the hypolipidwmic activity of gemfibrozil. Furthermore, the lack of correlation between the change of LPL and of serum triglyceride levels indicates that the role of the LPL in the action of the drug is variable from one patient to another. A decrease of VLDL production by gemfibrozil is in fact suggested by the studies of Kissebah et al. (1976) .
Its high hypolipidwmic efficiency and its few side effects make gemfibrozil a promising new compound in the treatment of hypertriglyceridwmia. An additional advantage is the slight elevation of plasma HDL by the drug. On the negative side remains the increase of LDL in some cases and this effect should receive particular attention in future studies in order to avoid a situation where the concentration of a strongly atherogenic lipoprotein is increased at the cost of decreasing another, probably much less dangerous one.
Summary
The hypolipidaemic effect of a new drug, gemfibrozil (CI-719), was studied for 20 weeks in 20 patients with primary type IIb, III, IV or V hyperlipoproteinemia. Baseline recordings of serum cholesterol (9.1 mmol/l), triglyceride (3.79 mmol/l) and ultra-centrifugally isolated lipoproteins were obtained during a six-week pretreatment period with stable diet and body weight.
With 800 mg of gemfibrozil per day given in two divided doses, the mean serum triglyceride and cholesterol levels were decreased by 44.6% and 10.5% respectively, during 20 treatment weeks. Only 2 patients were completely resistant to the hypolipidaemic action of the drug. Serum triglyceride was brought down to normal levels in 9 subjects. After 12 weeks of treatment the mean VLDL-triglyceride, VLDL-cholesterol, and LDL-triglyceride were reduced by 48.5 %, 57.6 %, and 22.7% respectively, while the HDL-cholesterol rose by 16 %. The LDL-cholesterol increased slightly but significantly during treatment in type IV patients and decreased in type IIb patients. The change of LDL-cholesterol showed an inverse correlation with the initial LDLcholesterol level (r= -0.87).
The postheparin plasma lipoprotein lipase and hepatic lipase activities, determined separately by an immunochemical method, increased during four weeks of gemfibrozil treatment (+18. 1% and 4-20.6% respectively), but neither of these changes was significantly correlated with the changes in any of the serum lipid or lipoprotein levels. Oral glucose tolerance was not influenced by the treatment, but one-hour plasma insulin increased slightly during administration of the drug. One patient discontinued the drug after eight weeks because of generalized allergic eczema, but no other side effects were recorded.
It is concluded that gemfibrozil is highly effective in reducing elevated serum VLDL levels. The simultaneous elevation of LDL in type IV patients needs more attention and study. The mechanism of the hypolipidemic action of the drug is so far obscure, but it might partly be due to an increased efficiency in VLDL removal by an increased activity of lipoprotein lipase.
